| A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. |
Completed |
Macitentan (ACT-064992, Opsumit ®) |
3 |
67896062CTP3001 |
King Fahad Medical City (Riyadh) |
| "A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity of Arabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56 Years and Above in Saudi Arabia" |
Completed |
Meningococcal Conjugate Vaccine (MenACWY-CRM) (Aramen) |
3b |
ARA/001/16 |
KKUH |
| A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age |
Rejected |
Infanrix-IPV/HiberixTM/SynflorixTM/GSK 134612 |
3b |
114858 |
KFMC |
| A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART) |
Terminated |
Lutropin alfa |
3b |
EMR200061_506 |
KAUH-J |
| A Phase III, Randomized, doublE-blind, placebo-controlled trial to evaluate Immunogenicity and Safety of the Gam-COVID-Vac combined vector vaccine in prophylactic Treatment for SARS-СoV-2 infection in Saudi Arabia |
Completed |
Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection. |
3 |
RC20/497/R |
King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer |
Ongoing |
DOCETAXEL Paclitaxel TAMOXIFEN Letrozole |
3 |
S1007 |
KFSH & RC-R |
| "A Phase III, Open-label, Randomized Study To Evaluate The Efficacy And Safety of Adjuvant Alectinib Versus Adjuvant Platinum-based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors≥4 Cm) To Stage IIIa Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer " |
Completed |
ALECTINIB |
3 |
BO40336 |
KFSH&RC-R |
| A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk |
Completed |
BI 10773 |
3 |
1245.25 |
KFMC |
| A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. |
Ongoing |
Evobrutinib |
3 |
MS200527ˍ0082 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
| "A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)" |
Ongoing |
Crizanlizumab |
3 |
CSEG101A2301 |
King Fahad Medical City (Riyadh) |
